Health Canada Updates Drug-Shortage Guidance on Reporting, Imports and Expiry Dates

Health Canada issued revisions to six guidance documents covering drug and medical-device shortages on October 7, 2026. The drug updates address shortage and discontinuation reporting, exceptional importation and sale, and batch-specific expiry-date extensions. Most of the requirements described are directed to market authorization holders and drug establishment licence holders; for pharmacists, the immediate value is understanding how the revised pathways may affect supply and what they do not authorize.

A framework update, not a general import permission

The October package includes revised versions of Health Canada’s drug-shortage reporting guide (GUI-0120) and exceptional-importation guide (GUI-0148), alongside a new guide for extending expiry dates of marketed drugs during shortages (GUI-0500). Related medical-device shortage documents were also updated. These are administrative guides that explain how regulated parties comply with the Food and Drug Regulations; they are not themselves new legislation. Where guidance and law conflict, the regulations prevail.

That distinction matters at the pharmacy counter. The revision to GUI-0148 does not allow a pharmacy to source any foreign-labelled product on its own initiative. The framework is limited to eligible foreign-authorized drugs that Health Canada accepts as substitutes for a Canadian DIN product facing a shortage or discontinuation that could pose a risk of injury to human health. Eligible products must be listed through the federal process, and importers and sellers remain subject to the applicable conditions.

Reporting now covers a broader scope

GUI-0120, issued in version 2 on October 7, broadens the range of drugs subject to mandatory shortage and discontinuation reporting by incorporating an Expanded Scope List into the framework. Health Canada also amended discontinuation reporting requirements and addressed drugs that have not been sold for 12 months. The statutory reporting duties remain aimed at market authorization holders; the guide also explains information that may be requested from market authorization and drug establishment licence holders.

For pharmacists, broader and more consistent manufacturer reporting can improve visibility of supply gaps and give health systems more time to plan. It does not shift the manufacturer’s reporting role to individual community pharmacies. Local teams should continue to use their established shortage-escalation channels and consult Health Canada’s public shortage information when evaluating alternatives.

More situations may qualify for exceptional sale

The revised GUI-0148 expands the framework to include, among other things, certain drugs made in Canada for foreign markets and foreign-authorized drugs considered in response to discontinuations, not only shortages. Health Canada may also require additional restrictions on the sale of a foreign drug and has clarified adverse-reaction responsibilities for regulated parties. The underlying exceptional-importation framework has existed in the regulations since 2022; the new guide explains its revised scope and conditions.

When a foreign-authorized product is listed, the packaging, language, product information, or usual supply route may differ from the Canadian-labelled version. Pharmacists should verify the exact product and its terms on the official list, check the accompanying product information, and follow applicable provincial, institutional, and professional requirements before dispensing. A listing is not a blanket statement that every foreign-market presentation is interchangeable in every clinical circumstance.

Expiry extensions remain batch-specific and evidence-based

GUI-0500 describes a separate shortage measure: Health Canada may extend the printed expiry date for a specified drug batch when the regulatory criteria are met and sufficient stability evidence supports the proposed date. The accepted batch and extension are added to the federal Extended Expiration Date List. This is a manufacturer/regulated-party proposal and Health Canada review process—not permission for a pharmacy to extend dates locally. A batch that is not listed, or that has passed its authorized extended date, should not be treated as covered by the measure.

Together, the revisions make the federal shortage toolkit more explicit about reporting, foreign-authorized supply, discontinuations, and limited use of remaining stock. They do not guarantee that a supply gap will be filled or that a substitute will be available in every province. The practical benefit depends on timely reporting, transparent product conditions, and communication among manufacturers, wholesalers, health systems, regulators, and pharmacy teams.

Practice guidance for pharmacists

• Check Health Canada’s current shortage notices and exceptional-importation list before relying on older notices, saved product lists, or informal supplier updates.
• For a listed foreign-authorized product, verify the exact name, strength, dosage form, market label, and any restrictions; review the supplied product information before dispensing.
• Do not independently extend a product’s expiry date. Confirm any claimed extension against the exact batch on Health Canada’s Extended Expiration Date List.
• Use your pharmacy or institution’s shortage escalation and documentation process, and communicate supply-related changes to the prescriber and patient when clinically relevant.
• Report suspected adverse reactions through the applicable Canadian reporting pathway, including the batch and any extended-expiry status when relevant.